Santarus Jumps Last Hurdle for Submitting NDA on Key Blockbuster Drug Budesonide MMX (SNTS, $2.79)Sunday, October 2, 2011 · 8:57 am |
|
An In-Depth Look at Santarus as it Develops a Promising Pipeline to Offset Patent Challenges to Existing Products (SNTS, $3.14)Friday, September 16, 2011 · 9:23 am |
|
Budesonide MMX's Potential in Ulcerative Colitis (SNTS, $3.18)Wednesday, September 14, 2011 · 2:13 pm |
|
Rhucin in the Hereditary Angioedema Market Can Be A Meaningful New Product for Santarus (SNTS, $3.14)Thursday, September 8, 2011 · 9:50 am |
|
Building a New Company on Zegerid's Ashes (SNTS, $2.24)Friday, June 3, 2011 · 1:21 pm |
|
Zegerid's Patents Are Ruled Invalid (SNTS, $5.36)Friday, June 3, 2011 · 1:06 pm |
|
Par Launches Generic Zegerid At Risk (SNTS, $4.55)Friday, June 3, 2011 · 1:00 pm |
|
Details on Par's Challenge to Zegerid Parents (SNTS, $3.30)Friday, June 3, 2011 · 12:45 pm |
|
Update on Santarus (SNTS, $1.78)Friday, June 3, 2011 · 9:54 am |
|
|
There are 9 reports on file. |
